Brendan David Curti MD

Clinical Trials

• Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer Start of enrollment: 2005 May 01

  Terminated

  Phase 2

• Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC) Start of enrollment: 2009 Jul 01

  Terminated

  Phase 2

• Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2010 Jun 01

  Withdrawn

  Phase 2

• A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) Start of enrollment: 2011 Dec 29

  Completed

  Phase 2

• Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14

  Completed

  Phase 1

• PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01

  Completed

• Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01

  ACTIVE_NOT_RECRUITING

  PHASE2

• Stereotactic Radiation and OX40 in Patients With Breast Cancer Metastatic to the Liver or Lung Start of enrollment: 2012 Feb 01
• HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01

  Terminated

  Phase 4

• Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Start of enrollment: 2012 Apr 27

  Completed

  Phase 1

• Chemoimmunotherapy and Radiation in Pancreatic Cancer Start of enrollment: 2013 Jul 01

  Completed

  Phase 1

• Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer Start of enrollment: 2013 Jul 01

  Completed

  Phase 2

• Phase I Study of Safety and Immunogenicity of ADU-623 Start of enrollment: 2014 Jan 08

  Completed

  Phase 1

• Immunoscore in Rectal Cancer Start of enrollment: 2014 Jan 24

  Completed

• Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2014 May 08

  Completed

  Phase 1

• α-TEA in Advanced Cancer Start of enrollment: 2014 Aug 04

  Completed

  Phase 1

• High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2014 Nov 26

  Terminated

  Phase 2

• A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Start of enrollment: 2014 Sep 15

  Completed

  Phase 1

• Pilot Study of DRibble Vaccine for Prostate Cancer Patients Start of enrollment: 2014 Oct 24

  Completed

  Phase 1

• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Start of enrollment: 2018 Sep 21

  COMPLETED

  PHASE3

• Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Start of enrollment: 2019 Apr 03

  ACTIVE_NOT_RECRUITING

  PHASE2

• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Start of enrollment: 2017 Sep 20

  RECRUITING

  PHASE2

• Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma Start of enrollment: 2019 Oct 28

  Active, not recruiting

  Phase 3

• PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) Start of enrollment: 2023 Mar 15

  RECRUITING

  PHASE1, PHASE2

  Roles: Contact

• Join now to see all